STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Rhea-AI Summary
Eli Lilly announces positive results from LIBRETTO-531 study on Retevmo for advanced thyroid cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
News
Lilly Completes Acquisition of Versanis Bio
Rhea-AI Summary
Eli Lilly and Company completes acquisition of Versanis Bio, expanding its portfolio with bimagrumab
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
acquisition
-
News
Lilly Completes Acquisition of Sigilon Therapeutics
Rhea-AI Summary
Eli Lilly completes acquisition of Sigilon Therapeutics, enabling research and development of cell therapies for type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
acquisition
News
Lilly Completes Acquisition of DICE Therapeutics
Rhea-AI Summary
Eli Lilly and Company has successfully completed its acquisition of DICE Therapeutics, expanding its immunology portfolio. The acquisition includes DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors for treating chronic diseases in immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
Rhea-AI Summary
Eli Lilly Q2 2023 revenue increased 28% to $8.31 billion, driven by volume growth and sale of rights for Baqsimi. EPS increased 86% to $1.95. Positive results in Alzheimer's and obesity studies. Acquisitions of DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.87%
Tags
earnings
-
News
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced topline results from the LIBRETTO-431 study, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Retevmo as an initial treatment for patients with RET fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). Adverse events observed were consistent with those identified across the previously reported Retevmo development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
News
Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announces impressive results from phase 3 tirzepatide studies, with participants achieving up to 26.6% mean weight loss over 84-88 weeks. The overall safety profile of tirzepatide was similar to previously reported trials, with gastrointestinal-related adverse events being the most common.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
-
News
Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
earnings
-
News
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
Rhea-AI Summary
LLY: Jardiance Approved by European Commission for Chronic Kidney Disease Treatment - Boehringer Ingelheim and Eli Lilly announce the approval of Jardiance for the treatment of chronic kidney disease by the European Commission. The approval is based on the results from EMPA-KIDNEY, which showed a significant benefit of empagliflozin in reducing the relative risk of kidney disease progression or cardiovascular death by 28 percent vs. placebo in people with CKD. With existing indications in type 2 diabetes and heart failure, empagliflozin could help manage the risks of cardio-renal-metabolic conditions, which are often interconnected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
News
Lilly Announces Extension of Tender Offer to Acquire DICE
Rhea-AI Summary
Eli Lilly and Company has extended the expiration of the tender offer to acquire all of the issued and outstanding shares of DICE Therapeutics, Inc. The purchase price is $48 per share in cash. The tender offer has been extended until August 8, 2023. Approximately 20.05% of the shares have been tendered as of July 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
acquisition
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#9 Ranked by Market Cap
#348 Ranked by Stock Gains
#1937 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.